All In Biotech

Drug Trial Radar · NCT06517758

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Iptacopan in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

146

Planned (sponsor's estimate)

Start

Jul 31, 2024

Primary completion

Apr 30, 2027

Study completion May 27, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • IptacopanDrug

    Hard gelatin capsule

  • Matching PlaceboOther

    Hard gelatin capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total scoreTime frame: Baseline to Month 6

Locations

116 sites in 18 countries. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona

  • Fullerton Neuro and Headache Ctr

    Fullerton, California

  • California Pacific Medical Center

    Sacramento, California

  • Augusta University Georgia

    Augusta, Georgia

  • University of Chicago Medical Centr

    Chicago, Illinois

  • Prairie Heart Institute

    Springfield, Illinois

  • Mid Atlantic Epilepsy and Sleep Ctr

    Bethesda, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Duke University Medical Center

    Durham, North Carolina

  • Penn Presbyterian Medical Center

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical CenterX

    Nashville, Tennessee

  • Nerve and Muscle Center of Texas

    Houston, Texas

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Argentina

  • Novartis Investigative Site

    Caba, Argentina

  • Novartis Investigative Site

    Capital Federal, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Camperdown, Sydney, Australia

  • Novartis Investigative Site

    Bahia, Brazil

  • Novartis Investigative Site

    São Paulo, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Joinville, Santa Catarina, Brazil

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Fujian, China

  • Novartis Investigative Site

    Jinan, China

  • Novartis Investigative Site

    Hefei, Anhui, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Shenzhen, Guangdong, China

  • Novartis Investigative Site

    Shijiazhuang, Hebei, China

  • Novartis Investigative Site

    Changsha, Hunan, China

  • Novartis Investigative Site

    Suzhou, Jiangsu, China

  • Novartis Investigative Site

    Xi'an, Shaanxi, China

  • Novartis Investigative Site

    Xianyang, Shaanxi, China

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.